MedTrace Logo

Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway

NCT07629167 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-06-05

No results posted yet for this study

Summary

A phase 2 study testing the efficacy of isotretinoin versus doxycycline in treating participants who develop a acneiform rash caused by standard of care, tumor-directed therapies targeting the mitogenactivated protein kinase (MAPK) pathway.

Conditions

  • Acneiform Drug Eruption
  • Acneiform Eruptions

Interventions

DRUG

Isotretinoin

Given Orally

DRUG

Doxycycline

Given Orally

PROCEDURE

Blood specimen collection

Perform blood draw

OTHER

Photographs of Rash

Undergo photography

BEHAVIORAL

Questionnaires

Participants will be asked to complete questionnaires

PROCEDURE

Stool Specimen collection

Perform stool sample collection

Sponsors & Collaborators

Principal Investigators

  • Sabine Mueller, MD, PhD, MAS · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-30
Primary Completion
2029-08-30
Completion
2030-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629167 on ClinicalTrials.gov